Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium; Symmons DP, Lunt M; British Society for Rheumatology Biologics Register. Hyrich KL, et al. Rheumatology (Oxford). 2009 Oct;48(10):1323-7. doi: 10.1093/rheumatology/kep242. Epub 2009 Aug 25. Rheumatology (Oxford). 2009. PMID: 19706737 Free PMC article. Clinical Trial.
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, Kiely P, Bukhari M, Abernethy R, Ostor A, Bosworth A, Gadsby K, McKenna F, Finney D, Dixey J; on behalf of BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR. Deighton C, et al. Among authors: bukhari m. Rheumatology (Oxford). 2010 Mar 22. doi: 10.1093/rheumatology/keq006b. Online ahead of print. Rheumatology (Oxford). 2010. PMID: 20308120 No abstract available.
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, Kiely P, Bukhari M, Abernethy R, Ostor A, Bosworth A, Gadsby K, McKenna F, Finney D, Dixey J; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR. Deighton C, et al. Among authors: bukhari m. Rheumatology (Oxford). 2010 Jun;49(6):1197-9. doi: 10.1093/rheumatology/keq006a. Epub 2010 Mar 22. Rheumatology (Oxford). 2010. PMID: 20308121 No abstract available.
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Galloway JB, et al. Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31. Rheumatology (Oxford). 2011. PMID: 20675706 Free PMC article.
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. Ding T, et al. Among authors: bukhari m. Rheumatology (Oxford). 2010 Nov;49(11):2217-9. doi: 10.1093/rheumatology/keq249a. Epub 2010 Sep 12. Rheumatology (Oxford). 2010. PMID: 20837498 No abstract available.
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
Bukhari M, Abernethy R, Deighton C, Ding T, Hyrich K, Lunt M, Luqmani R, Kiely P, Bosworth A, Ledingham J, Ostör A, Gadsby K, McKenna F, Finney D, Dixey J; BSR and BHPR Standards, Guidelines and Audit Working Group. Bukhari M, et al. Rheumatology (Oxford). 2011 Dec;50(12):2311-3. doi: 10.1093/rheumatology/ker106a. Epub 2011 May 4. Rheumatology (Oxford). 2011. PMID: 21546351 No abstract available.
421 results